Efficacy of boosted protease inhibitor monotherapy in patients with complex medical problems

AIDS

Volumn 21, Issue 13, 2007, Pages 1821-1823

  Garrett, Nigel J ^a   Matin, Nasha ^a   Edwards, Simon G ^a   Miller, Robert F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; COMORBIDITY; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RATING SCALE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ACUTE DISEASE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; VIRAL LOAD;

EID: 34547729855     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328270389b     Document Type: Article

References (10)

1. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society - USA panel. JAMA 2006; 296:827-843.
2. Kahlert C, Hupfer M, Wagels T, Bueche D, Fierz W, Walker UA, et al. Ritonavir boosted indinavir treatment as a simplified maintenance 'mono'-therapy for HIV infection. AIDS 2004; 18:955-956.
3. Ebrahim O, Hill A. Short-course induction with boosted saquinavir monotherapy for naÏve patients with late-stage infection. AIDS 2005; 19:211-212.
4. Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-287.
5. Campo RE, Lalanne R, Tanner TJ, Jayaweera DT, Rodriguez AE, Fontaine L, et al. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2005; 19:447-449.
6. Morris A, Masur H, Huang L. Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med 2006; 34:239-240.
7. Chemlal K, Nochy D, Kenouch S, Joly V, Carbon C. Dramatic improvement of renal dysfunction in a human immunodeficiency virus-infected woman treated with highly active antiretroviral therapy. Clin Infect Dis 2000; 31:805-806.
8. Miller RF, Scully M, Cohen H, Roedling S, Starke R, Edwards SG, et al. Thrombotic thrombocytopaenic purpura in HIV-infected patients. Int J STD AIDS 2005; 16:538-542.
9. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-7469.
10. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:238-243.